Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-11

Study Completion Date

2017-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare serum ketone body (i.e., total ketones, β hydroxybutyrate, and estimate of acetoacetate) levels after single dose administration of AC-1202 and 2 doses of AC-SD-01.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778

NCT02858271

Healthy

COMPLETED PHASE1

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

NCT01462786

Healthy

COMPLETED PHASE1

A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

NCT03400995

Healthy

COMPLETED PHASE1

Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

NCT01319916

Healthy

COMPLETED PHASE1

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

NCT04268953

Alzheimer Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

16 healthy subjects enrolled, each subject will receive 1 dose of each treatment, with a 2 day washout in between.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group ABC

AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)

Group Type EXPERIMENTAL

AC-1202

Intervention Type DRUG

60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1

AC-SD-01 (50 g)

Intervention Type DRUG

50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

AC-SD-01 (75 g)

Intervention Type DRUG

75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

Group BCA

AC-SD-01 (50g), AC-SD-01 (75g), AC-1202

Group Type EXPERIMENTAL

AC-1202

Intervention Type DRUG

60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1

AC-SD-01 (50 g)

Intervention Type DRUG

50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

AC-SD-01 (75 g)

Intervention Type DRUG

75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

Group CAB

AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)

Group Type EXPERIMENTAL

AC-1202

Intervention Type DRUG

60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1

AC-SD-01 (50 g)

Intervention Type DRUG

50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

AC-SD-01 (75 g)

Intervention Type DRUG

75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AC-1202

60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1

Intervention Type DRUG

AC-SD-01 (50 g)

50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

Intervention Type DRUG

AC-SD-01 (75 g)

75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy, adult, male 19-55 years of age, inclusive, at screening.
2. Continuous non smoker who has not used nicotine containing products for at least 3 months prior to Day -1 of Period 1 and throughout the study.
3. Body mass index (BMI) ≥ 20.0 and ≤ 30.0 kg/m2 at screening.
4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) \< the upper limit of normal and triglyceride levels must be \< 250 mg/dL.
5. A non vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Day -1 of Period 1. A subject who has been vasectomized less than 4 months prior to Day -1 of Period 1 must follow the same restrictions as a non vasectomized male).
6. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria

1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
4. History or presence of alcoholism or drug abuse within the past 2 years prior to Day -1 of Period 1.
5. History or presence of galactosemia or hypersensitivity or idiosyncratic reaction to the study drugs, related compounds, milk, palm or coconut oil, or soy.
6. History or presence of diverticular disease, ulcers, inflammatory bowel disease or recurrent diarrhea or gout.
7. Positive urine drug or alcohol results at screening or check in.
8. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
9. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
10. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
11. QTcF interval is \> 460 msec or subject has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.
12. Estimated creatinine clearance ≤ 80 mL/min at screening.
13. Unable to refrain from or anticipates the use of any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to Day -1 of Period 1 and throughout the study. Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study.
14. Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 28 days prior to Day -1 of Period 1 and throughout the study.
15. Is lactose intolerant.
16. Is unable to complete the meal prior to Hour 0 on Day -1 of Period 1 and prior to dosing on Day 1 of Period 1.
17. Subject consumed grapefruit or Seville oranges within 14 days prior to Day -1 of Period 1.
18. Donation of blood or significant blood loss within 56 days prior to Day -1 of Period 1.
19. Plasma donation within 7 days prior to Day -1 of Period 1.
20. Participation in another clinical study within 28 days prior to Day -1 of Period 1. The 28 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day -1 of Period 1 of the current study.

Minimum Eligible Age

19 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes